REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis
Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.
How this was made

The 30-second read
Why it matters
The FDA approval is a pivotal regulatory milestone for REGN’s neurology pipeline, supported by Phase 3 NIMBLE efficacy at week 24 and an outlined safety framework via boxed warning and REMS distribution.
Market read
Traders can reprice REGN’s neurology and RNAi exposure immediately due to a first-in-class siRNA approval, with quantified efficacy and defined safety constraints.
What to watch
The article does not quantify expected patient penetration, pricing, or uptake; traders may need to wait for post-approval guidance, payer coverage signals, and real-world safety/REMS logistics.
Background
Livsayis (cemdisiran) is a C5-directed siRNA therapy intended to reduce terminal complement activation, a key driver in generalized myasthenia gravis.
Ticker impact
Regeneron said the FDA approved Livsayis (cemdisiran) for anti-AChR antibody-positive generalized myasthenia gravis, based on positive Phase 3 NIMBLE results.
Likely upward bias as the market prices in commercialization upside and de-risks the regulatory pathway for this asset.
The article is a direct FDA approval with Phase 3 efficacy metrics and safety boxed warning details, which are typically material for valuation and positioning.
Market effects
Strengthens the RNAi/siRNA platform narrative in neurology and may lift sentiment for complement-targeting approaches in autoimmune neuromuscular disease.
Potential read-through to EU regulatory expectations for the same asset, with a stated decision window in 2H 2027.
Supports global commercialization expectations for RNAi therapeutics, with additional filings planned including Japan.
Counterpoint
The boxed warning for serious meningococcal infections and restricted REMS could limit uptake and increase monitoring costs, tempering near-term revenue expectations.
Key entities
- companyRegeneron Pharmaceuticals
Sponsor of Livsayis, receiving FDA approval for generalized myasthenia gravis in anti-AChR antibody-positive adults.
- drugLivsayis (cemdisiran)
C5-directed siRNA therapy approved for gMG, administered subcutaneously four times per year.
- companyAlnylam
Licensing partner for development, manufacturing, and commercialization under a worldwide licensing agreement.
- regulatorFDA
Approved Livsayis based on Phase 3 NIMBLE study results.
- clinical_trialNIMBLE study
Phase 3 trial providing the efficacy data cited for FDA approval.




